CHOSA Oncology – executive interview

CHOSA Oncology – executive interview

Chosa — 2 videos in collection

More on this equity

In this video we speak with Peter Buhl Jensen, CEO of CHOSA Oncology, and Claus Frisenberg, the company’s CFO. Chosa is a Scandinavian biotechnology company focused on the development of its proprietary drug response predictor (DRP). In the interview, Peter and Claus cover how the DRP helps stratify cancer patients who are most likely to respond to platinum chemotherapy, the data that Chosa has acquired to support its application in various cancer types, and the potential to use it in combination regimens with an immunotherapy partner. Peter and Claus also outline Chosa’s regulatory and commercial strategy, as well as key catalysts and milestones to watch out for over the next 12 months.


You may also be interested in these:

Healthcare

Executive interview - RhoVac

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.